“Anika has become a dynamic guest-oriented apple. The advent of these state-of-the-art technologies shows that the apple is listening to its medical clients detect the purposes of surgeons and patients, and that it has the strength to develop, download approvals and launch a chain of new devices and instruments, even within the framework of a pandemic.” said Cheryl R. Blanchard, Ph.D., President and CEO of Anika. “The intelligent construction and commercial expansion in the position of the sports medicine market and the preservation and recovery of joints require a low prestige of the unsatisfied desires of patients and the strength to transcend the comments of surgeons due into symptoms that are significant and practical for today’s smallest friend invasive surgical ecosystem. Anika is well placed to launch these innovative innovations, and we move forward to introduce these new products to our next guest base as COVID restrictions become more undeniable and optional procedures resume in the United States.
New includes:
“Unintelligible intellectual innovations consisting of techniques, machinery and fabrics are essential in joint preservation surgery, allowing surgeons to continue with the best friend refinement tactics to reassert their active and comfortable patients,” said Anil S. Ranawat, M.D., Hospital for Special Surgery. “Having worked hard with Anika’s team over the past few years, I am encouraged by their ability to detect clinical disorders and get real-time responses for us as professionals. Your next arsenal of new machinery is the excess lacheck of this commitment, and I advance to put them into practice.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global incorporated preservation, recovery and joint regeneration company that responds to Apple’s apple founded in Bedford, Massachusetts. Anika is committed to providing a diverse diversity of products to patients’ lives, with a focus on managing arthrotic pain, sports medicine and joint preservation, recovery and regeneration. The combined apple has virtually the best friend 3 decades of global experience in marketing cutting-edge products circulating the continuum of orthopedic early intervention care. For additional information about Anika, visit www.anikatherapeutics.com.
Forward-looking statements
The statements made in the first and third sentence of the first paragraph, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s planned product launches. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors, especially in light of the evolving landscape around the COVID-19 pandemic. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s failure to realize the anticipated benefits of its recently completed acquisitions; (ii) unexpected expenditures or assumed liabilities that may be incurred as a result of these acquisitions; (iii) loss of key employees or customers following the acquisitions or otherwise; (iv) unanticipated difficulties in conforming business practices, including accounting policies, procedures, internal controls, and financial records of the recently acquired companies; (v) inability to accurately forecast the performance of the recently acquired companies resulting in unforeseen adverse effects on the Company’s operating results; (vi) synergies between the recently acquired companies and the Company being estimates which may be materially different from actual results; (vii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (viii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (ix) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (x) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (xi) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (xii) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.